Cargando…
Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer
BACKGROUND: Drug resistance is a significant problem in the treatment of ovarian cancer and can be caused by multiple mechanisms. Inhibition of apoptosis by the inhibitor of apoptosis proteins (IAPs) represents one such mechanism, and can be overcome by a mitochondrial protein called second mitochon...
Autores principales: | Garg, Gunjal, Vangveravong, Suwanna, Zeng, Chenbo, Collins, Lynne, Hornick, Mary, Hashim, Yassar, Piwnica-Worms, David, Powell, Matthew A, Mutch, David G, Mach, Robert H, Hawkins, William G, Spitzer, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015918/ https://www.ncbi.nlm.nih.gov/pubmed/24602489 http://dx.doi.org/10.1186/1476-4598-13-50 |
Ejemplares similares
-
The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer
por: Binder, Pratibha S., et al.
Publicado: (2022) -
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer
por: Hashim, Yassar M., et al.
Publicado: (2017) -
Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer
por: Zeng, C, et al.
Publicado: (2013) -
Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer
por: Hornick, John R, et al.
Publicado: (2012) -
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3
por: Garg, Gunjal, et al.
Publicado: (2014)